Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Checked against the public recordLast updated Jun 22, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Exelixis
- Interventions being studied
- Drug: XB010; Drug: Pembrolizumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
* Age 18 years or older on the day of consent. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. * Adequate organ and marrow function. * Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent. * The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer). * Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- City of Hope Orange County Lennar Foundation Cancer CenterIrvine, California
- UCLA Department of Medicine - Hematology/OncologyLos Angeles, California
- Georgetown University Medical CenterWashington D.C., District of Columbia
- Sarah Cannon Research Institute at Florida Cancer SpecialistsOrlando, Florida
- Winship Cancer InstituteAtlanta, Georgia
- University of Chicago Medical CenterChicago, Illinois
- Siteman Cancer CenterSt Louis, Missouri
- Montefiore Medical Center - Montefiore Medical ParkThe Bronx, New York
- Carolina BioOncology InstituteHuntersville, North Carolina
- Stephenson Cancer CenterOklahoma City, Oklahoma
- SCRI Oncology PartnersNashville, Tennessee
- NEXT AustinAustin, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 22, 2026. Always confirm current availability with the study team.